2015
Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]
Paidas M, Frieling J, de Jongh J, Drenth H, Streisand J. Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149]. Obstetrics And Gynecology 2015, 125: 52s. DOI: 10.1097/01.aog.0000463689.71574.8f.Peer-Reviewed Original ResearchEarly-onset preeclampsiaRecombinant human antithrombinPhase 3 trialPopulation pharmacokinetic modelingHuman antithrombinAntithrombin deficiencyPlasma antithrombinPharmacokinetic modelingHereditary antithrombin deficiencyPopulation pharmacokinetic modelAntithrombin activity levelsDifferent pharmacokinetic propertiesPrior human studiesExpectant managementPerinatal morbidityPregnant patientsLoading doseMaternal administrationPregnant womenContinuous infusionSimilar efficacyClinical studiesPleiotropic effectsAntithrombin treatmentDose selection
2013
Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1)
Paidas MJ, Sibai BM, Triche EW, Frieling J, Lowry S, Group T. Exploring the Role of Antithrombin Replacement for the Treatment of Preeclampsia: A Prospective Randomized Evaluation of the Safety and Efficacy of Recombinant Antithrombin in Very Preterm Preeclampsia (PRESERVE‐1). American Journal Of Reproductive Immunology 2013, 69: 539-544. PMID: 23444920, DOI: 10.1111/aji.12091.Peer-Reviewed Original ResearchConceptsProspective Randomized EvaluationAntithrombin replacementWeeks' gestationRandomized EvaluationRecombinant antithrombinTreatment of preeclampsiaRecombinant human ATExpectant managementPreterm preeclampsiaPrimary endpointMaternal indicationsGestational ageStudy enrollmentAT therapyPreeclampsia studyPreeclampsiaGestationHuman ATAT replacementPharmacokinetic activityAntithrombinEfficacySafetyLaboratory assaysDelivery